Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

The primary objective of this study was to conduct a cost-utility analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease. A multicenter prospective study was conducted across 12 Spanish hospitals from May 2020 to April 2022, involving 158 patients with hypercholesterolemia or atherosclerotic cardiovascular disease. This study assessed health-related quality of life (QoL) using the EQ-5D-3L questionnaire. The cost-utility analysis evaluated the economic impact of PCSK9 inhibitors when used with standard care compared to standard care alone, calculating the incremental cost-effectiveness ratio (ICER). This study included 158 patients with an average age of 61 years, male (66.5%). For patients initiating PCSK9 inhibitors, the treatment cost was EUR 13,633.39, while standard therapy cost EUR 3638.25 over two years. QoL for PCSK9 inhibitors stood at 1.6489 over two years, compared to 1.4548 for standard therapy. The results revealed favorable cost-utility outcomes, with an ICER of EUR 51,427.72. Significant improvements were observed in the domains of mobility, self-care, daily activities, pain/discomfort, and anxiety/depression (<i>p</i> < 0.001). This study presents the first real-world cost-utility analysis of PCSK9 inhibitors, supporting their economic rationale and highlighting their benefits in clinical practice. Healthcare decision-makers can use these results to inform their decisions and reimbursement policies concerning PCSK9 inhibitors. Trial Registration clinicaltrials.gov Identifier: NCT04319081.

Authors

Institutions

Publication Details

Journal
Diseases
Published
2024-10-05
DOI
https://doi.org/10.3390/diseases12100244
Citations
3
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
1.72

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

Alberto Cordero, Pedro Suárez‐Artime, Ana Rodríguez-Vázquez, Diego Rodríguez‐Penas et al.
3 citations
Diseases
Lipoproteins and Cardiovascular Health
1.72
article

Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

Alberto Cordero, Pedro Suárez‐Artime, Ana Rodríguez-Vázquez, Diego Rodríguez‐Penas, José Seijas‐Amigo, Ana Estany‐Gestal, Laura Villaverde-Piñeiro, José Ramón González‐Juanatey, Mónica Gayoso‐Rey, Octavio Cordova-Arevalo, Antonia Casas-Martínez, Francisco Reyes-Santías, Natalia Pérez-Rodríguez, Lara González-Freire, E Espino-Paisan, Moisés Rodríguez‐Mañero, Concepción Castro-Rubinos, Begoña Cardeso-Paredes, Marta Ribeiro-Ferreiro, Maria José Mauriz-Montero
article en
3 citations

Abstract

The primary objective of this study was to conduct a cost-utility analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease. A multicenter prospective study was conducted across 12 Spanish hospitals from May 2020 to April 2022, involving 158 patients with hypercholesterolemia or atherosclerotic cardiovascular disease. This study assessed health-related quality of life (QoL) using the EQ-5D-3L questionnaire. The cost-utility analysis evaluated the economic impact of PCSK9 inhibitors when used with standard care compared to standard care alone, calculating the incremental cost-effectiveness ratio (ICER). This study included 158 patients with an average age of 61 years, male (66.5%). For patients initiating PCSK9 inhibitors, the treatment cost was EUR 13,633.39, while standard therapy cost EUR 3638.25 over two years. QoL for PCSK9 inhibitors stood at 1.6489 over two years, compared to 1.4548 for standard therapy. The results revealed favorable cost-utility outcomes, with an ICER of EUR 51,427.72. Significant improvements were observed in the domains of mobility, self-care, daily activities, pain/discomfort, and anxiety/depression (<i>p</i> < 0.001). This study presents the first real-world cost-utility analysis of PCSK9 inhibitors, supporting their economic rationale and highlighting their benefits in clinical practice. Healthcare decision-makers can use these results to inform their decisions and reimbursement policies concerning PCSK9 inhibitors. Trial Registration clinicaltrials.gov Identifier: NCT04319081.

DiseasesVol. 12(10)
Universidade de Santiago de Compostela (ES), University Hospital Complex Of Vigo (ES), Centro de Investigación en Red en Enfermedades Cardiovasculares (ES), Complejo Hospitalario Universitario de Santiago (ES), Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (ES), Centro de Investigación Biomédica en Red (ES), Hospital General Universitario de Elche (ES), Complexo Hospitalario Universitario A Coruña (ES), Instituto de Investigación Sanitaria de Santiago (ES), Hospital Comarcal de Inca (ES), Hospital Marina Baixa (ES), Complejo Hospitalario de Pontevedra (ES), Complejo Hospitalario de Ourense (ES), Complejo Hospitalario Universitario de Ferrol (ES), Universidade de Vigo (ES)
Fundación Instituto de Investigación Sanitaria de Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago de Compostela, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares
Openalex Percentile: Top 15%
Lipoproteins and Cardiovascular Health
1.72
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.